Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27397628 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KDM4EPOLBHTT | |
| SCHEMBL28685165 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KDM4EPOLBHTT | |
| SCHEMBL27591991 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KDM4EPOLBHTT | |
| Water SCHEMBL27519090 | 0.97 | ALDH1A1 (0.59) | ALDH1A1HSD17B10KDM4EPOLBHTT | |
| SCHEMBL30484132 | 0.95 | ALDH1A1 (0.58) | ALDH1A1HSD17B10KDM4EPOLBHTT | |
| SCHEMBL1207100 | 0.95 | ALDH1A1 (0.58) | ALDH1A1HSD17B10KDM4EPOLBHTT | |
| SCHEMBL7170901 | 0.89 | SOAT1 (0.53) | ALDH1A1HSD17B10KDM4EPOLBMEN1 | |
| SCHEMBL4230481 | 0.87 | ALDH1A1 (0.55) | ALDH1A1HSD17B10KDM4EPOLBMAPT | |
| SCHEMBL15964195 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EPOLBMAPT | |
| SCHEMBL9631015 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KDM4EPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220125778-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-0157656-A3 | Process and intermediates for the preparation of aryl substituded pyrido [1,4] benzodiazepines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-07-15 | — | — | EP | disclosed |
| US-4628100-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-12-09 | — | — | US | disclosed |
| US-4560510-A | CONDENSATION OF AN AMINOCHLOROPYRIDINE WITH A ARYL(AMINOPHENYL)METHANONE WITH A BASE) | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-24 | — | — | US | disclosed |
| US-4560510-A | CONDENSATION OF AN AMINOCHLOROPYRIDINE WITH A ARYL(AMINOPHENYL)METHANONE WITH A BASE) | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0157656-A2 | Process and intermediates for the preparation of aryl substituded pyrido [1,4] benzodiazepines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-09 | — | — | EP | disclosed |
| EP-0157656-A2 | Process and intermediates for the preparation of aryl substituded pyrido [1,4] benzodiazepines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-09 | — | — | EP | disclosed |
| US-4518603-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-05-21 | — | — | US | disclosed |
| US-4480100-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1984-10-30 | — | — | US | disclosed |
| US-3899527-A | Intermediates for the preparation of 1,3-dihydro-2H-1,4-benzodiazepin-2-ones | AMERICAN HOME PROD | 1975-08-12 | — | — | US | disclosed |
| US-3883591-A | Intermediates for the preparation of 1,3-dihydro-2H-1,4-benzodiazepin-2-ones | AMERICAN HOME PROD | 1975-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125778-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, ENGASE | ALDH1A1 406/4885HSD17B10 331/4885KDM4E 3801/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | ALDH1A1 2834/4885HSD17B10 1853/4885KDM4E 4383/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | ALDH1A1 1655/4885HSD17B10 2850/4885KDM4E 3023/4885 |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | ALDH1A1 3373/4885HSD17B10 3288/4885KDM4E 4166/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | ALDH1A1 373/4885HSD17B10 305/4885KDM4E 3671/4885 |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, UGT2B7 | ALDH1A1 550/4885HSD17B10 351/4885KDM4E 3709/4885 |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | ALDH1A1 3373/4885HSD17B10 3288/4885KDM4E 4166/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | ALDH1A1 2834/4885HSD17B10 1853/4885KDM4E 4383/4885 |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | ALDH1A1 3373/4885HSD17B10 3288/4885KDM4E 4166/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | ALDH1A1 2834/4885HSD17B10 1853/4885KDM4E 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.